The interplay between inflammation and metabolism in rheumatoid arthritis

Cell Death and Disease

Volumn 6, Issue , 2015, Pages

  Chimenti, M S ^a   Triggianese, P ^a   Conigliaro, P ^a   Candi, E ^a   Melino, G ^a,b   Perricone, R ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADIPOCYTOKINE; APC; CELECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; METHOTREXATE; NAPROXEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB;

ATHEROSCLEROSIS; CLINICAL FEATURE; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; METABOLISM; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; CHRONIC DISEASE; COMPLICATION; PATHOLOGY;

ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; HUMANS; INFLAMMATION;

EID: 84952306311     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.246     Document Type: Review

References (108)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-2219.
2. Zordan P, Rigamonti E, Freudenberg K, Conti V, Azzoni E, Rovere-Querini P et al. Macrophages commit postnatal endothelium-derived progenitors to angiogenesis and restrict endothelial to mesenchymal transition during muscle regeneration. Cell Death Dis 2014; 5: e1031.
3. Través PG, Pardo V, Pimentel-Santillana M, González-Rodríguez Á, Mojena M, Rico D et al. Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge. Cell Death Dis 2014; 5: e1125.
4. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-3545.
5. Raychaudhuri S. Recent advances in the genetics of rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 109-118.
6. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977-986.
7. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B et al. TRAF1-C5 as a risk locus for rheumatoid arthritis: a genomewide study. N Engl J Med 2007; 357: 1199-1209.
8. Hu R, Chen ZF, Yan J, Li QF, Huang Y, Xu H et al. Complement C5a exacerbates acute lung injury induced through autophagy-mediated alveolar macrophage apoptosis. Cell Death Dis 2014; 5: e1330.
9. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8: R133.
10. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis 2014; 5: e1102.
11. Tarner IH, Harle P, Muller-Ladner U, Gay RE, Gay S. The different stages of synovitis: acute vs chronic, early vs late and non-erosive vs erosive. Best Pract Res Clin Rheumatol 2005; 19: 19-35.
12. Lettieri Barbato D, Aquilano K, Baldelli S, Cannata SM, Bernardini S, Rotilio G et al. Proline oxidase-adipose triglyceride lipase pathway restrains adipose cell death and tissue inflammation. Cell Death Differ 2014; 21: 113-123.
13. Mihaly SR, Ninomiya-Tsuji J, Morioka S. TAK1 control of cell death. Cell Death Differ 2014; 21: 1667-1676.
14. Jongbloed SL, Lebre MC, Fraser AR, Gracie JA, Sturrock RD, Tak PP et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther 2006; 8: R15.
15. Reis AC, Alessandri AL, Athayde RM, Perez DA, Vago JP, Ávila TV et al. Induction of eosinophil apoptosis by hydrogen peroxide promotes the resolution of allergic inflammation. Cell Death Dis 2015; 6: e1632.
16. Yang L, Karin M. Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ 2014; 21: 1677-1686.
17. Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ 2015; 22: 526-539.
18. Su Z, Yang R, Zhang W, Xu L, Zhong Y, Yin Y et al. The synergistic interaction between the calcineurin B subunit and IFN-γ enhances macrophage antitumor activity. Cell Death Dis 2015; 6: e1740.
19. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-1352.
20. Summersgill H, England H, Lopez-Castejon G, Lawrence CB, Luheshi NM, Pahle J et al. Zinc depletion regulates the processing and secretion of IL-1β. Cell Death Dis 2014; 5: e1040.
21. Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 202-213.
22. Li L, Ng DS, Mah WC, Almeida FF, Rahmat SA, Rao VK et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell Death Differ 2015; 22: 1081-1093.
23. Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z et al. Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis. Cell Death Differ 2014; 21: 1229-1239.
24. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther 2005; 7(Suppl 2): S4-S14.
25. Scott DL, Steer S. The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 943-967.
26. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev 2011; 11: 123-131.
27. Sárvári AK, Doan-Xuan QM, Bacsó Z, Csomós I, Balajthy Z, Fésüs L. Interaction of differentiated human adipocytes with macrophages leads to trogocytosis and selective IL-6 secretion. Cell Death Dis 2015; 6: e1613.
28. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10: 582-589.
29. Turesson C, Matteson EL. Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 2007; 19: 190-196.
30. Gabriel SE, Crowson CS. Risk factors for cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24: 171-176.
31. Oren P, Farnham AE, Milofsky M, Marnovsky ML. Metabolic patterns in three types of phagocytizing cells. J Cell Biol 1963; 17: 487-501.
32. He Z, Liu H, Agostini M, Yousefi S, Perren A, Tschan MP et al. p73 regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene. Cell Death Differ 2013; 20: 1415-1424.
33. Humphries F, Yang S, Wang B, Moynagh PN. RIP kinases: key decision makers in cell death and innate immunity. Cell Death Differ 2015; 22: 225-236.
34. Bennett WE, Cohn ZA. The isolation and selected properties of blood monocytes. J Exp Med 1966; 123: 145-159.
35. Arwadi MS, Newsholme EA. Maximum activities of some enzymes of glycolysis, the CS cycle and ketone body and glutamine utilization pathways in lymphocytes of the rat. Biochem J 1982; 208: 743-748.
36. Rodriguez-Prados JC, Través PG, Cuenca J, Rico D, Aragonés J, Martín-Sanz P et al. Substrate fate in activated macrophages: a comparison between innate, classic and alternative activation. J Immunol 2010; 185: 605-614.
37. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR et al. HIF-1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 2011; 208: 1367-1379.
38. Yin YW, Liao SQ, Zhang MJ, Liu Y, Li BH, Zhou Y et al. TLR4-mediated inflammation promotes foam cell formation of vascular smooth muscle cell by upregulating ACAT1 expression. Cell Death Dis 2015; 6: 1659.
39. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y et al. Control of TH17/Treg balance by hypoxia-inducible factor 1. Cell 2011; 146: 772-784.
40. Van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 2012; 36: 68-78.
41. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012; 58: 139-147.
42. Baron L, Gombault A, Fanny M, Villeret B, Savigny F, Guillou N et al. The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine. Cell Death Dis 2015; 6: e1629.
43. Kim SR, Kim DI, Kim SH, Lee H, Lee KS, Cho SH et al. NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis 2014; 5: e1498.
44. Qin Y, Chen Y, Wang W, Wang Z, Tang G, Zhang P et al. HMGB1-LPS complex promotes transformation of osteoarthritis synovial fibroblasts to a rheumatoid arthritis synovial fibroblast-like phenotype. Cell Death Dis 2014; 5: e1077.
45. Hiebert PR, Wu D, Granville DJ. Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein E knockout mice. Cell Death Differ 2013; 20: 1404-1414.
46. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011; 35: 871-882.
47. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudostarvation. Nature 2013; 493: 346-355.
48. Alonso R, Mazzeo C, Rodriguez MC, Marsh M, Fraile-Ramos A, Calvo V et al. Diacylglycerol kinase α regulates the formation and polarisation of mature multivesicular bodies involved in the secretion of Fas ligand- containing exosomes in T lymphocytes. Cell Death Differ 2011; 18: 1161-1173.
49. Li W, Ren G, Huang Y, Su J, Han Y, Li J et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012; 19: 1505-1513.
50. Cencioni MT, Santini S, Ruocco G, Borsellino G, De Bardi M, Grasso MG et al. FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients. Cell Death Dis 2015; 6: e1741.
51. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature 2013; 499: 485-490.
52. Krawczyk C, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ et al. Toll-like receptorinduced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010; 115: 4742-4749.
53. Ewald F, Annemann M, Pils MC, Plaza-Sirvent C, Neff F, Erck C et al. Constitutive expression of murine c-FLIPR causes autoimmunity in aged mice. Cell Death Dis 2014; 5: e1168.
54. Tanner DC, Campbell A, O'Banion KM, Noble M, Mayer-Pröschel M. cFLIP is critical for oligodendrocyte protection from inflammation. Cell Death Differ 2015; 22: 1489-1501.
55. Sanders MG, Parsons MJ, Howard AG, Liu J, Fassio SR, Martinez JA et al. Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes. Cell Death Dis 2015; 6: e1813.
56. Chimenti MS, Tucci P, Candi E, Perricone R, Melino G, Willis AE. Metabolic profiling of human CD4+ cells following treatment with methotrexate and anti-TNF-α infliximab. Cell Cycle 2013; 12: 3025-3036.
57. Priori R, Scrivo R, Brandt J, Valerio M, Casadei L, Valesini G et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev 2013; 12: 1022-1030.
58. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65: 1448-1456.
59. Chen X, Gan Y, Li W, Su J, Zhang Y, Huang Y et al. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis 2014; 5: e1009.
60. Abella V, Scotece M, Conde J, López V, Lazzaro V, Pino J et al. Adipokines, metabolic syndrome and rheumatic diseases. J. Immunol Res 2014; 2014: 343746.
61. Fabre O, Breuker C, Amouzou C, Salehzada T, Kitzmann M, Mercier J et al. Defects in TLR3 expression and RNase L activation lead to decreased MnSOD expression and insulin resistance in muscle cells of obese people. Cell Death Dis 2014; 5: e1136.
62. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
63. Crowson CS, Myasoedova E, Davis JM 3rd, Matteson EL, Roger VL, Therneau TM et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011; 38: 29-35.
64. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, crosssectional, controlled, study. Ann Rheum Dis 2007; 66: 28-33.
65. Uutela T, Kautiainen H, Järvenpää S, Salomaa S, Hakala M, Häkkinen A. Waist circumference based abdominal obesity may be helpful as a marker for unmet needs in patients with RA. Scand J Rheumatol 2014; 43: 279-285.
66. Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011; 7: 528-536.
67. Kontunen P, Vuolteenaho K, Nieminen R, Lehtimäki L, Kautiainen H, Kesäniemi Y et al. Resistin is linked to inflammation, and leptin to metabolic syndrome, in women with inflammatory arthritis. Scand J Rheumatol 2011; 40: 256-262.
68. Procaccini C, De Rosa V, Galgani M, Carbone F, La Rocca C, Formisano L et al. Role of adipokines signaling in the modulation of T cells function. Front Immunol 2013; 4: 332.
69. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V et al. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 2005; 335: 1254-1263.
70. Senolt L, Pavelka K, Housa D, Haluzík M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006; 35: 247-252.
71. Frommer KW, Zimmermann B, Meier FM, Schröder D, Heil M, Schäffler A et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010; 62: 2886-2899.
72. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758.
73. Proto JD, Tang Y, Lu A, Chen WC, Stahl E, Poddar M et al. NF-κB inhibition reveals a novel role for HGF during skeletal muscle repair. Cell Death Dis 2015; 6: e1730.
74. Chen TH, Swarnkar G, Mbalaviele G, Abu-Amer Y. Myeloid lineage skewing due to exacerbated NF-κB signaling facilitates osteopenia in Scurfy mice. Cell Death Dis 2015; 6: e1723.
75. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56: 2829-2839.
76. Kim YH, Choi BH, Cheon HG, Do MS. B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation. Exp Mol Med 2009; 41: 208-216.
77. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
78. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4: R5.
79. Madsen RK, Lundstedt T, Gabrielsson J, Sennbro CJ, Alenius GM, Moritz T et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther 2011; 13: R19.
80. Buckley MG, Walters C, Wong WM, Cawley MI, Ren S, Schwartz LB et al. Mast cell activation in arthritis: detection of α- and β-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci (Lond) 1997; 93: 363-370.
81. Goodman MN. Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 1991; 260: E727-E730.
82. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-1697.
83. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012; 224: 309-317.
84. Violi F, Basili S, Nigro C, Pignatelli P. Role of NADPH oxidase in atherosclerosis. Future Cardiol 2009; 5: 83-92.
85. Lavrik IN. Systems biology of death receptor networks: live and let die. Cell Death Dis 2014; 5: e1259.
86. Datta S, Kundu S, Ghosh P, De S, Ghosh A, Chatterjee M. Correlation of oxidant status with oxidative tissue damage in patients with rheumatoid arthritis. Clin Rheumatol 2014; 33: 1557-1564.
87. Ishibashi T. Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases. Curr Pharm Des 2013; 19: 6375-6381.
88. Park YJ, Kim JY, Park J, Choi JJ, Kim WU, Cho CS. Bone erosion is associated with reduction of circulating endothelial progenitor cells and endothelial dysfunction in rheumatoid arthritis. Arthritis Rheum 2014; 66: 1450-1460.
89. Dimitroulas T, Sandoo A, Veldhuijzen van Zanten JJ, Smith JP, Hodson J, Metsios GS et al. Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scand J Rheumatol 2013; 42: 176-178.
90. Provan SA, Semb AG, Hisdal J, Stranden E, Agewall S, Dagfinrud H et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a crosssectional comparative study. Ann Rheum Dis 2011; 70: 812-817.
91. Bradham WS, Ormseth MJ, Oeser A, Solus JF, Gebretsadik T, Shintani A et al. Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator. Inflammation 2014; 37: 801-808.
92. Chimenti MS, Graceffa D, Perricone R. Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: Is it possible after disease remission? Autoimmun Rev 2011; 10: 636-640.
93. Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN et al. Long- term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167-175.
94. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013; 12: 599-606.
95. Maini R St, Clair EW, Breedveld F, Furst D, Kalden J,Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-1939.
96. Weinblatt ME, van Riel PL. Targeted therapies: summary clinical trials working group. Ann Rheum Dis 2006; 65: iii89.
97. Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFα mediated by the PKC-MAPKs-AP-1 pathway. Cell Death Differ 2011; 18: 26-37.
98. Takata M, Nakagomi T, Kashiwamura S, Nakano- Doi A, Saino O, Nakagomi N et al. Glucocorticoid- induced TNF receptor-triggered T cells are key modulators for survival/ death of neural stem/progenitor cells induced by ischemic stroke. Cell Death Differ 2012; 19: 756-767.
99. Geering B, Simon HU. A novel signaling pathway in TNFα-induced neutrophil apoptosis. Cell Cycle 2011; 10: 2821-2822.
100. Christofferson DE, Li Y, Hitomi J, Zhou W, Upperman C, Zhu H et al. A novel role for RIP1 kinase in mediating TNFα production. Cell Death Dis 2012; 3: e320.
101. Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Di Muzio G, Ballanti E et al. Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol 2014; 177: 234-243.
102. Carrillo-de Sauvage MÁ, Maatouk L, Arnoux I, Pasco M, Sanz Diez A, Delahaye M et al. Potent and multiple regulatory actions of microglial glucocorticoid receptors during CNS inflammation. Cell Death Differ 2012; 20: 1546-1557.
103. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 2010; 1193: 153-159.
104. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010; 5: e14328.
105. Preyat N, Rossi M, Kers J, Chen L, Bertin J, Gough PJ et al. Intracellular nicotinamide adenine dinucleotide promotes TNF-induced necroptosis in a sirtuin-dependent manner. Cell Death Differ; e-pub ahead of print 22 May 2015.
106. Spinelli FR, Metere A, Barbati C, Pierdominici M, Iannuccelli C, Lucchino B et al. Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators Inflamm 2013; 2013: 537-539.
107. Danninger K, Hoppe UC, Pieringer H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis 2014; 17: 606-611.
108. Ballanti E, Perricone C, Di Muzio G, Kroegler B, Chimenti MS, Graceffa D et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 2011; 10: 617-623.